SCHEMBL22200656

SCHEMBL22200656

CNc1ncc2nc(-c3cc(F)c(NSCCC(F)(F)F)c(F)c3)c(=O)n(C(C)C)c2n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.48
CYP1A2 P05177 17/20 0.39
ALDH1A1 P00352 14/20 0.39
CASP1 P29466 14/20 0.39
CASP7 P55210 14/20 0.39
USP2 O75604 13/20 0.39
HSD17B10 Q99714 12/20 0.39
MEN1 O00255 10/20 0.39
KMT2A Q03164 10/20 0.39
HIF1A Q16665 10/20 0.39
CLK4 Q9HAZ1 4/20 0.39
GLA P06280 3/20 0.39
CYP2D6 P10635 8/20 0.37
CYP3A4 P08684 8/20 0.37
LMNA P02545 3/20 0.36
MAPK1 P28482 1/20 0.35
HBB P68871 3/20 0.35
HPGD P15428 3/20 0.35
ALOX15 P16050 2/20 0.35
BRCA1 P38398 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22200452 0.94 ERN1 (0.49) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200713 0.89 ERN1 (0.45) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200719 0.89 ERN1 (0.42) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200563 0.83 ERN1 (0.46) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200600 0.83 ERN1 (0.52) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200592 0.82 ERN1 (0.55) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200597 0.81 ERN1 (0.37) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200355 0.78 ERN1 (0.41) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200627 0.76 ERN1 (0.52) ERN1CYP1A2ALDH1A1CASP1CASP7
SCHEMBL22200574 0.75 ERN1 (0.34) ERN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020142612-A1 PYRIDO-PYRIMIDINONE AND PTERIDINONE COMPOUNDS AS INHIBITORS OF ENDORIBONUCLEASE INOSITOL REQUIRING ENZYME I (IRE I ALPHA) FOR THE TREATMENT OF CANCER DISEASES. GENENTECH, INC. (US) 2020-07-09 WO disclosed